The U.S. Food and Drug Administration (FDA) has officially finalized its long-awaited guidance regarding formal meetings between the agency and…
Read More
AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.
In the global effort to eradicate hepatitis C (HCV), clinical success has frequently collided with the sobering realities of public…
Read More
How Sheba Medical Center became OpenAI’s first international hospital partner
The landscape of global healthcare is undergoing a seismic shift as Sheba Medical Center, Israel’s largest and most prominent healthcare…
Read More
The oral exposure challenge in PROTACs: What drug developers need to solve early
The landscape of modern pharmacology shifted fundamentally in May 2026 with the U.S. Food and Drug Administration’s approval of vepdegestrant,…
Read More
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
The landscape of oncology is currently undergoing a paradigm shift as pharmaceutical giants Merck & Co. and Moderna move toward…
Read More
2026 PharmSci 360 adds tracks on research credibility and post-animal drug development
The American Association of Pharmaceutical Scientists (AAPS) has announced a significant evolution for its flagship annual conference, PharmSci 360, which…
Read More
Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice
The global landscape of immunology has been irrevocably altered by the COVID-19 pandemic, leaving behind a massive, worldwide cohort of…
Read More
DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
The United States Drug Enforcement Administration (DEA) has initiated a significant regulatory crackdown on a burgeoning class of synthetic alkaloids…
Read More
After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice
For millions of cancer patients worldwide, the life-saving potential of chemotherapy is frequently tempered by a debilitating side effect known…
Read More
Pharma commercial vendor selection still runs on word of mouth: A Harvard MBA student aims to change that with Rx Almanac
For pharmaceutical companies navigating the complex journey from clinical trial success to market launch, the final hurdle is often the…
Read More
